Nyxoah to Present at Healthcare Conference
Nyxoah SA, a leader in medical technology focused on treating Obstructive Sleep Apnea (OSA), is poised to showcase its advancements at an upcoming prominent event. The company will take part in the Piper Sandler 36th Annual Healthcare Conference, scheduled for December 4. This notable event is set to provide a platform for Nyxoah to present their revolutionary treatment approaches and engage with potential investors.
Event Highlights
During the conference, Nyxoah’s presentation will begin at 2:00 PM ET, and interested stakeholders can tune in to the live audio webcast via the company’s investor relations website. This opportunity will allow attendees to hear directly from Nyxoah’s leadership about their cutting-edge solutions and strategic initiatives.
About Nyxoah and its Innovations
Nyxoah has made significant strides in reinventing how we approach sleep technology, especially for the estimated billion individuals grappling with OSA. At the forefront of their innovations, the Genio® device stands out. This battery-free hypoglossal neuromodulation device is a breakthrough, offering an alternative that can be implanted through a minimally invasive procedure beneath the chin. Patients can conveniently control the device through a wearable technology, prioritizing both effectiveness and user-friendliness.
Clinical Success and Market Impact
Following a series of successful clinical trials, including the notable BLAST OSA study, Nyxoah secured its European CE Mark recognition in 2019, marking a significant milestone. The company has since launched two successful IPOs, one on Euronext Brussels in September 2020 and another on NASDAQ in July 2021. These achievements underscore Nyxoah’s commitment to fostering innovation within the sleep treatment sector.
Recent Developments
In light of recent findings from the BETTER SLEEP study, Nyxoah has received CE mark approval to expand its therapeutic indications, now including patients with Complete Concentric Collapse (CCC)—a category often neglected by competitors. Moreover, the positive conclusions drawn from the DREAM IDE pivotal study are paving the way for FDA approval, which is crucial for entering the U.S. market.
Future Directions
The advancements made by Nyxoah reflect a dedication to precision medicine and are grounded in a clear vision to enhance patient outcomes. This focus not only sets the Genio® system apart but places Nyxoah in a dominant position in the landscape of sleep apnea treatments. Their continuous efforts are expected to drive further innovation, setting new industry standards.
Frequently Asked Questions
1. What is the purpose of the Piper Sandler Healthcare Conference?
The conference provides a platform for healthcare companies like Nyxoah to present their innovations and connect with investors and industry leaders.
2. What is the Genio® device?
The Genio® is a battery-free hypoglossal neuromodulation device developed by Nyxoah for treating obstructive sleep apnea through a minimally invasive procedure.
3. What recent approvals has Nyxoah received?
Nyxoah received the CE mark to expand its indications to include CCC patients and is progressing towards obtaining FDA approval for its products in the U.S.
4. How can stakeholders access Nyxoah's presentation?
Stakeholders can access the live audio webcast of Nyxoah's presentation through the investor relations section of their official website.
5. Who should be contacted for more information about Nyxoah?
For inquiries, parties can reach out to Nyxoah's CFO, John Landry, at IR@nyxoah.com for investor-related questions or media representatives in various regions for other inquiries.
